<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206960</article-id><article-id pub-id-type="doi">10.1101/2025.06.12.659426</article-id><article-id pub-id-type="archive">PPR1037467</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><italic>OnCorr</italic>: A pan-cancer mRNA-protein correla2on tool for precision oncology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nawaz</surname><given-names>Urwah</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Deng</surname><given-names>Niantao</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Livson</surname><given-names>Ori</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mayoh</surname><given-names>Chelsea</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lau</surname><given-names>Loretta M S</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Reddel</surname><given-names>Roger R</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Padhye</surname><given-names>Bhavna</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name><surname>Poulos</surname><given-names>Rebecca C</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>ProCan<sup>®</sup>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01bsaey45</institution-id><institution>Children’s Medical Research Institute</institution></institution-wrap>, Faculty of Medicine and Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0384j8v12</institution-id><institution>The University of Sydney</institution></institution-wrap>, <city>Westmead</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><aff id="A2"><label>2</label>Children’s Cancer Institute, Lowy Cancer Research Centre, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>UNSW Sydney</institution></institution-wrap>, <city>Sydney</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><aff id="A3"><label>3</label>School of Clinical Medicine, UNSW Medicine &amp; Health, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03r8z3t63</institution-id><institution>UNSW Sydney</institution></institution-wrap>, <city>Sydney</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><aff id="A4"><label>4</label>Kids Cancer Centre, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02tj04e91</institution-id><institution>Sydney Children’s Hospital</institution></institution-wrap>, <city>Sydney</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><aff id="A5"><label>5</label>Cancer Centre for Children, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05k0s5494</institution-id><institution>The Children’s Hospital at Westmead</institution></institution-wrap>, <city>Westmead</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><aff id="A6"><label>6</label>Kids Research, Children’s Cancer Research Unit, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05k0s5494</institution-id><institution>The Children’s Hospital at Westmead</institution></institution-wrap>, <city>Westmead</city>, <state>NSW</state>, <country country="AU">Australia</country></aff><author-notes><corresp id="CR1">
<label>*</label>Corresponding author. <email>rpoulos@cmri.org.au</email>.</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>07</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>17</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Proteins are ulGmately responsible for cellular phenotypes and are targeted by most anGcancer drugs. However, beyond immunohistochemistry, proteins are not typically measured in precision oncology, meaning transcriptomics is used as a proxy. To determine how informaGve mRNA is for guiding personalised treatments, mRNA-protein correlaGons were analysed in three large pan-cancer datasets and made available in a web portal (<ext-link ext-link-type="uri" xlink:href="https://procan.shinyapps.io/oncorr/">https://procan.shinyapps.io/OnCorr/</ext-link>). <italic>OnCorr</italic> can be integrated into precision medicine programs to augment transcriptomics.</p></abstract></article-meta></front><body><p id="P2">Precision medicine programs in oncology almost universally incorporate genomic data, usually via targeted sequencing panels, or more rarely whole genome sequencing, to detect somatic variants that aid diagnosis or choice of therapy<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. Some precision medicine initiatives also concurrently measure the transcriptome, with gene expression used to identify cancer subtypes or the upregulation of genes whose translated proteins correspond to known anti-cancer drug targets<sup><xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R4">4</xref></sup>. However, few precision medicine initiatives routinely incorporate proteomic data at scale<sup><xref ref-type="bibr" rid="R5">5</xref>–<xref ref-type="bibr" rid="R6">6</xref></sup>. This is a potential issue because most targeted anti-cancer agents that are recommended for personalised treatments directly inhibit a protein or pathway in a cancer cell<sup><xref ref-type="bibr" rid="R7">7</xref></sup>.</p><p id="P3">Due to the paucity of proteomic data generated in precision oncology, ultimately gene expression must be relied upon as a proxy for protein abundances – which typically remain unmeasured in a patient–s cancer. However, gene expression measurements are generally only moderately correlated with protein abundances, with correlations approximating 0.4-0.5<sup><xref ref-type="bibr" rid="R8">8</xref>–<xref ref-type="bibr" rid="R12">12</xref></sup>. Both technical and biological factors can influence mRNA-protein correlations, such as post-transcriptional regulation including protein degradation and differing rates of mRNA translation<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. Therefore, having accurate knowledge of how well mRNA expression levels predict protein abundances for any given gene would enhance decision-making in precision medicine. Here we present a freely available precision oncology tool called <italic>OnCorr</italic> to interrogate mRNA-protein correlations across cancer types, available at <ext-link ext-link-type="uri" xlink:href="https://procan.shinyapps.io/OnCorr/">https://procan.shinyapps.io/OnCorr/</ext-link>.</p><p id="P4">To assess pan-cancer mRNA-protein correlations, we first interrogated a multi-omic dataset of human cell lines spanning 6,692 proteins across over 40 cancer types<sup><xref ref-type="bibr" rid="R8">8</xref></sup>. This dataset (called ProCan-DepMapSanger) includes proteomics from data-independent acquisition mass spectrometry, acquired in a standardised laboratory<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup> across several technical replicates per cell line. The transcriptomics are from RNA-sequencing data available at Cell Model Passports<sup><xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>. First, the median Spearman’s mRNA-protein correlation was calculated for each gene-protein pair in this dataset across 19 tissue types that comprised measurements in at least 10 cell lines (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). mRNA-protein correlations in each tissue type ranged from 0.31-0.45, with a cohort-wide median gene-wise mRNA-protein correlation of 0.42, across 6,205 genes with both mRNA and protein measurements (<xref ref-type="fig" rid="F1">Fig. 1b</xref>).</p><p id="P5">Next, mRNA-protein correlations from the ProCan-DepMapSanger cell line dataset were compared with two other publicly available pan-cancer studies with both transcriptome and proteome data. These include a series of cancer tissue cohorts from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (<italic>n</italic> = 1,030 cancer samples available from LinkedOmics<sup><xref ref-type="bibr" rid="R18">18</xref></sup>), and a pan-cancer cell line dataset from the Cancer Cell Lines Encylopedia (CCLE) (n = 375 cell lines)<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Both datasets show a similar range in mRNA-protein correlations across tissue types (0.32 to 0.49; <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1a and Supplementary Figure 1b</xref>), with cohort-wide median correlations of 0.38 and 0.46 respectively (<italic>n</italic> = 14,465 and 10,437 genes; <xref ref-type="fig" rid="F1">Fig. 1c</xref>). While cancer cell lines do not always capture the underlying biology of patient tissue<sup><xref ref-type="bibr" rid="R7">7</xref></sup>, they do have the advantage of not being impacted by issues relating to tumour purity, which could have a small effect on mRNA-protein correlation<sup><xref ref-type="bibr" rid="R13">13</xref></sup>. The cell line datasets selected for this work were all measured in a single study and, in the case of the ProCan-DepMapSanger dataset, on a single instrument platform, which allows for robust comparisons of correlations between tissue types. Increasing confidence in these datasets, both cancer cell line studies showed consistent mRNA-protein correlations across key biological pathways and selected cancer-related pathways as has been previously described in cancer tissues<sup><xref ref-type="bibr" rid="R13">13</xref></sup> including those from CPTAC (Correlation of CPTAC with ProCan-DepMapSanger of <italic>r</italic> = 0.85 and with CCLE of <italic>r</italic> = 0.74; <xref ref-type="fig" rid="F1">Fig. 1d-e</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1c-d</xref>).</p><p id="P6">mRNA-protein correlations were next interrogated across genes that often act as cancer drivers, using a set of 1,161 cancer genes from OncoKB<sup><xref ref-type="bibr" rid="R19">19</xref></sup>. This set combines genes from cancer sequencing panels, the COSMIC Cancer Gene Census<sup><xref ref-type="bibr" rid="R20">20</xref></sup> and Vogelstein (2013)<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. For robust analyses, mRNA-protein correlations were calculated only for the subset of these cancer driver genes in which the encoded protein was measured in at least ten samples in a minimum of fifteen tissue types (i.e., missing in fewer than five tissues; <italic>n</italic> = 261 genes). Using the ProCan-DepMapSanger dataset, hierarchical clustering revealed five clusters of driver genes with differing ranges of mRNA-protein correlations (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). Cancer drivers had slightly higher median correlations than genes not identified as cancer drivers (median <italic>r</italic> = 0.41 and 0.39, respectively; P &lt; 0.0001 by unpaired Student’s t-test) (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). Among cancer drivers, one cluster of 50 genes had the highest mRNA-protein correlations across tissue types (Cluster 4; median <italic>r</italic> = 0.69) and is enriched for genes from pathways involved in chromatin binding and chromosome organisation (<xref ref-type="fig" rid="F2">Fig. 2c</xref>). Another cluster of 12 genes had the poorest mRNA-protein correlations (Cluster 1; Median <italic>r</italic> = 0.16) and is comprised of genes from pathways involved in transcription factor and RNA polymerase II binding (<xref ref-type="fig" rid="F2">Fig. 2c</xref>). Other clusters had genes with mRNA-protein correlations that varied considerably between tissue types. These patterns of mRNA-protein correlations among cancer driver genes could be replicated in the cancer tissue dataset from CPTAC (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2a</xref>) and the cancer cell line dataset from CCLE (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 2b</xref>).</p><p id="P7">The extent of correlation between any given gene and the protein that it encodes can be driven by both technical and biological factors<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>. Upadhya et al (2022)<sup><xref ref-type="bibr" rid="R22">22</xref></sup> developed a reproducibility rank to quantify the accuracy by which a protein can be measured by mass spectrometry. This ranking was shown to have a strong relationship with mRNA-protein correlation, suggesting that technical factors can influence the interpretation of such correlations. This association can also be observed in the ProCan-DepMapSanger (r = 0.49, <xref ref-type="fig" rid="F3">Fig. 3a</xref>), CPTAC (r = 0.40, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3a</xref>) and CCLE (r = 0.29, <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3b</xref>) datasets. Therefore, this reproducibility rank is a useful aid in the interpretation of mRNA-protein correlations, as an indicator of confidence in protein measurement accuracy across datasets and platforms</p><p id="P8">To demonstrate the utility of mRNA-protein correlations for precision medicine, 474 cancer driver genes with robust measurements (i.e., observed with a minimum of 10 measurements from at least one tissue type) were interrogated in detail. Of these, 129 cancer driver genes had an mRNA-protein correlation above 0.5 and a good protein reproducibility rank (&gt; 0.4; <xref ref-type="fig" rid="F3">Fig. 3b</xref>). For these genes, which include ALDH2, IDH2 and EGFR (<xref ref-type="fig" rid="F3">Fig. 3c</xref>), their transcriptome measurements should typically be considered a good predictor of protein abundance. In contrast, 30 cancer driver genes had mRNA-protein correlations below 0.25 while maintaining a good protein reproducibility rank (&gt; 0.4; <xref ref-type="fig" rid="F3">Fig. 3b</xref>). For these genes, which include CTNNB1 (<xref ref-type="fig" rid="F3">Fig. 3c</xref>), transcriptome measurements will typically be a poor predictor of protein abundance. Proteins translated from such genes may be unreliable targets when identified from gene expression alone within a precision oncology pipeline. To explore this further with CTNNB1 as an example, a poor mRNA-protein correlation (median <italic>r</italic> = 0.10) is observed in most tissues (<xref ref-type="fig" rid="F3">Fig. 3d</xref>). This suggests that in many tissues, outliers identified by RNA-sequencing (&gt; 3 standard deviations above the mean; <xref ref-type="fig" rid="F3">Fig. 3e</xref>) are unlikely to be highly expressed at the protein level (see outlier samples by RNA-seq in <xref ref-type="fig" rid="F3">Fig. 3f</xref>). Finally, other genes such as KMT2D (<xref ref-type="fig" rid="F3">Fig. 3c</xref>), have both low mRNA-protein correlations and poor reproducibility ranks. These genes have uncertain implications for precision oncology as a low mRNA-protein correlation may be a result of either biological factors such as posttranslational modifications or technical factors that influence protein measurement accuracy.</p><p id="P9">To make these mRNA-protein correlations accessible for precision medicine programs, the <italic>OnCorr</italic> web portal was built (<ext-link ext-link-type="uri" xlink:href="https://procan.shinyapps.io/OnCorr/">https://procan.shinyapps.io/OnCorr/</ext-link>). This platform enables the interrogation of mRNA-protein correlations alongside reproducibility ranks within an easy-to-navigate user interface (<xref ref-type="fig" rid="F4">Fig. 4</xref>). The tool integrates the ProCan-DepMapSanger, CPTAC and CCLE pan-cancer datasets, allowing the user to select their dataset of interest, as well as to filter and view results across all samples and by tissue type. This web portal is freely available and is designed to be interpretable by oncologists, researchers and data curators.</p><p id="P10">This study and associated data interpretation have several limitations. For some genes, different mRNA-protein correlations are observed across datasets. This could be a result of differences in cell culture conditions, proteomic data acquisition methods or differences in the cancer types that make up each tissue annotation. Also, many of the datasets included in this study compare RNA-sequencing data acquired from a temporally or spatially different specimen than was used for the mass spectrometry analyses, leading to a false reduction in the measured mRNA-protein correlation. Finally, some genes, such as CDK4 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3c</xref>), show patient outliers in mRNA expression (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3d</xref>) that remain highly expressed at the protein level (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 3e</xref>) despite what would be suggested by the overall mRNA-protein correlation and reproducibility rank for these genes (CDK4: <italic>r</italic> = 0.14 correlation and 0.51 reproducibility rank). Therefore, inclusion of mRNA-protein correlations in precision oncology should be considered as one piece of information alongside several other metrics that, together, will drive the choice of targeted agents from a patient’s molecular profile.</p><p id="P11">In summary, <italic>OnCorr</italic> can be used in precision oncology initiatives to augment transcriptomic findings in the absence of proteomic data to inform a patient’s personalised treatment options. It can also be adopted for research to interrogate mRNA-protein correlations across three independent pan-cancer datasets. <italic>OnCorr</italic> is available at <ext-link ext-link-type="uri" xlink:href="https://procan.shinyapps.io/oncorr/">https://procan.shinyapps.io/OnCorr/</ext-link>.</p><sec id="S1" sec-type="methods"><title>Methods</title><sec id="S2"><title>Raw data sources</title><p id="P12">All data analysed in this study are publicly available from three independent datasets. Data from ProCan-DepMapSanger are available from Gongalves et al <sup><xref ref-type="bibr" rid="R8">8</xref></sup>. Data from the Clinical Proteomics Tumor Analysis Consortium (CPTAC) were downloaded from the LinkedOmicsKB database<sup><xref ref-type="bibr" rid="R18">18</xref></sup>. Data from the Cancer Cell Line Encyclopedia (CCLE) are available from Nusinow et al <sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Tissue type annotations were harmonised as in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>.</p></sec><sec id="S3"><title>Correlation analysis</title><p id="P13">To calculate mRNA-protein correlations, a spearman rank correlation was performed for each mRNA-protein pair across all samples. Analyses were restricted to proteins with measurements in at least 10 cell lines for both RNA-seq and proteomics datasets to reduce any biases arising from proteins with measurements only in very few samples. For correlation analysis of mRNA-protein pairs within each tissue, cancers were grouped based on their tissue of origin and analysis was restricted to tissues that contained at least 10 cell lines in the relevant dataset.</p></sec><sec id="S4"><title>Functional enrichment</title><p id="P14">For biological pathways shown in <xref ref-type="fig" rid="F1">Fig. 1d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1c</xref>, pathways and their associated genes were retrieved from Sanchez-Vega et al <sup><xref ref-type="bibr" rid="R23">23</xref></sup> and KEGG pathways<sup><xref ref-type="bibr" rid="R24">24</xref></sup>, where <italic>Homo sapiens</italic> genes were retrieved from the msigdbr package (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/msigdbr/index.html">https://cran.r-project.org/web/packages/msigdbr/index.html</ext-link>). The median Spearman correlation rank was calculated for genes in each pathway per tissue type.</p></sec><sec id="S5"><title>Analysis of cancer driver genes</title><p id="P15">A list of 1,169 cancer driver genes was obtained from the OncoKB portal<sup><xref ref-type="bibr" rid="R19">19</xref></sup>. For heatmap and clustering analyses, genes were retained if they had mRNA-protein correlations in ≥15 tissue types (i.e., missing in fewer than 5 out of 19 tissues). The heatmap at <xref ref-type="fig" rid="F2">Fig. 2c</xref> was plotted using the pheatmap package (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/pheatmap/index.html">https://cran.r-project.org/web/packages/pheatmap/index.html</ext-link>), which uses complete hierarchical clustering, and Euclidean distance as a similarity measure. The function <italic>cutree</italic> with the option k=5 was used to retrieve the driver genes in each cluster. Gene ontology analysis for each cluster was performed using clusterProfiler<sup><xref ref-type="bibr" rid="R25">25</xref></sup>. Only ontologies that had an FDR adjusted p-value &lt; 0.05 were retained.</p></sec><sec id="S6"><title>Correlation analysis with reproducibility ranks</title><p id="P16">Aggregated protein-protein reproducibility ranks were retrieved from Upadhya et al <sup><xref ref-type="bibr" rid="R22">22</xref></sup>. Ranks were binned for plotting and Spearman’s correlations were reported from unbinned data.</p></sec><sec id="S7"><title>Statistical analyses</title><p id="P17">All analyses were carried out in Python version 3.12.1, and R version 4.3.2, using the pandas library (Python), and dplyr, Gdyverse and reshape2 (R). All plots were made using ggplot2 (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggplot2/index.html">https://cran.r-project.org/web/packages/ggplot2/index.html</ext-link>), and extensions ggdist (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggdist/index.html">https://cran.r-project.org/web/packages/ggdist/index.html</ext-link>), ggpubr (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggpubr/index.html">https://cran.r-project.org/web/packages/ggpubr/index.html</ext-link>) and ggbeeswarm (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggbeeswarm/index.html">https://cran.r-project.org/web/packages/ggbeeswarm/index.html</ext-link>).</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Material</label><media xlink:href="EMS206960-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="d68aAcLbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S8"><title>Acknowledgements</title><p>ProCan is supported by the Australian Cancer Research Foundation, Cancer Institute New South Wales (NSW) (2017/TPG001, REG171150, 2021/CBG0002), NSW Ministry of Health (CMP-01), the University of Sydney, Cancer Council NSW (IG 18-01), Ian Potter Foundation, the Medical Research Future Fund (MRFF-PD), National Health and Medical Research Council (NHMRC) of Australia European Union grant (GNT1170739, a companion grant to support the ‘iPC-individualized Paediatric Cure’ [ref. 826121]), and National Breast Cancer Foundation (IIRS-18-164). Work at ProCan is done under the auspices of a Memorandum of Understanding between Children’s Medical Research Institute and the U.S. National Cancer Institute’s International Cancer Proteogenome Consortium (ICPC) that encourages cooperation among institutions and nations in proteogenomic cancer research in which datasets are made available to the public. R. C. P. and B. P. are supported by a Sydney Cancer Partners Translational Partners Fellowship with funding from a Cancer Institute NSW Capacity Building Grant (grant ID 2021/CBG0002). L. M. S. L. is funded by a CINSW Program Grant (no. 2021/TPG2112) and NHMRC Synergy Grant (APP2018642). This work was supported by NHMRC (GNT2000855, GNT1138536).</p></ack><sec id="S9" sec-type="data-availability"><title>Data and code availability</title><p id="P18">The datasets analysed during the current study are available in Gongalves et al <sup><xref ref-type="bibr" rid="R8">8</xref></sup>, the LinkedOmicsKB database<sup><xref ref-type="bibr" rid="R18">18</xref></sup> and Nusinow et al <sup><xref ref-type="bibr" rid="R9">9</xref></sup>. The underlying code for this study is available in GitHub and can be accessed via <ext-link ext-link-type="uri" xlink:href="https://github.com/CMRI-procan/OnCorr">www.github.com/CMRI-procan/OnCorr</ext-link>.</p></sec><fn-group><fn id="FN1" fn-type="con"><p id="P19"><bold>Author contributions</bold></p><p id="P20">R.C.P designed and directed the project. U. N. and R. C. P. analysed the data and wrote the manuscript. U.N. and O.L. built the <italic>OnCorr</italic> web tool. N. D. contributed statstcal oversight of analyses. C.M., L. M. S. L., R. R. R., B. P. and R.C.P. interpreted the results and the implicatons for clinical implementaton. All authors discussed the results and contributed to the final manuscript.</p></fn><fn id="FN2" fn-type="conflict"><p id="P21"><bold>Competing interests</bold></p><p id="P22">The authors declare no competing interests</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mateo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Delivering precision oncology to patients with cancer</article-title><source>Nat Med</source><year>2022</year><volume>28</volume><fpage>658</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">35440717</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsimberidou</surname><given-names>AM</given-names></name><name><surname>Fountzilas</surname><given-names>E</given-names></name><name><surname>Bleris</surname><given-names>L</given-names></name><name><surname>Kurzrock</surname><given-names>R</given-names></name></person-group><article-title>Transcriptomics and solid tumors: The next frontier in precision cancer medicine</article-title><source>Semin Cancer Biol</source><year>2022</year><volume>84</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2020.09.007</pub-id><pub-id pub-id-type="pmcid">PMC11927324</pub-id><pub-id pub-id-type="pmid">32950605</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>LMS</given-names></name><etal/></person-group><article-title>Precision-guided treatment in high-risk pediatric cancers</article-title><source>Nat Med</source><year>2024</year><volume>30</volume><fpage>1913</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1038/s41591-024-03044-0</pub-id><pub-id pub-id-type="pmcid">PMC11271405</pub-id><pub-id pub-id-type="pmid">38844796</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsakiroglou</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>A</given-names></name><name><surname>Pirmohamed</surname><given-names>M</given-names></name></person-group><article-title>Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis</article-title><source>Front Genet</source><year>2023</year><volume>14</volume><elocation-id>1100352</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2023.1100352</pub-id><pub-id pub-id-type="pmcid">PMC10036914</pub-id><pub-id pub-id-type="pmid">36968610</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boys</surname><given-names>EL</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Robinson</surname><given-names>PJ</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name></person-group><article-title>Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?</article-title><source>Proteomics</source><year>2023</year><volume>23</volume><elocation-id>e2200238</elocation-id><pub-id pub-id-type="pmid">35968695</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padhye</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities</article-title><source>Pediatr Blood Cancer</source><year>2024</year><volume>71</volume><elocation-id>e30980</elocation-id><pub-id pub-id-type="pmid">38556739</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulos</surname><given-names>RC</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Robinson</surname><given-names>PJ</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name></person-group><article-title>Opportunities for pharmacoproteomics in biomarker discovery</article-title><source>Proteomics</source><year>2023</year><volume>23</volume><elocation-id>e2200031</elocation-id><pub-id pub-id-type="pmid">36086888</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonçalves</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pan-cancer proteomic map of 949 human cell lines</article-title><source>Cancer Cell</source><year>2022</year><volume>40</volume><fpage>835</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2022.06.010</pub-id><pub-id pub-id-type="pmcid">PMC9387775</pub-id><pub-id pub-id-type="pmid">35839778</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nusinow</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Quantitative Proteomics of the Cancer Cell Line Encyclopedia</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>387</fpage><lpage>402</lpage><elocation-id>e16</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2019.12.023</pub-id><pub-id pub-id-type="pmcid">PMC7339254</pub-id><pub-id pub-id-type="pmid">31978347</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasaikar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1035</fpage><lpage>1049</lpage><elocation-id>e19</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2019.03.030</pub-id><pub-id pub-id-type="pmcid">PMC6768830</pub-id><pub-id pub-id-type="pmid">31031003</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Integrated proteogenomic characterization of human high-grade serous ovarian cancer</article-title><source>Cell</source><year>2016</year><volume>166</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.069</pub-id><pub-id pub-id-type="pmcid">PMC4967013</pub-id><pub-id pub-id-type="pmid">27372738</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Beyer</surname><given-names>A</given-names></name><name><surname>Aebersold</surname><given-names>R</given-names></name></person-group><article-title>On the Dependency of Cellular Protein Levels on mRNA Abundance</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>535</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">27104977</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghoshdastider</surname><given-names>U</given-names></name><name><surname>Sendoel</surname><given-names>A</given-names></name></person-group><article-title>Exploring the pan-cancer landscape of posttranscriptional regulation</article-title><source>Cell Rep</source><year>2023</year><volume>42</volume><elocation-id>113172</elocation-id><pub-id pub-id-type="pmid">37742190</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulos</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Strategies to enable large-scale proteomics for reproducible research</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><elocation-id>3793</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-17641-3</pub-id><pub-id pub-id-type="pmcid">PMC7393074</pub-id><pub-id pub-id-type="pmid">32732981</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tully</surname><given-names>B</given-names></name><etal/></person-group><article-title>Addressing the challenges of high-throughput cancer tissue proteomics for clinical application: ProCan</article-title><source>Proteomics</source><year>2019</year><volume>19</volume><elocation-id>e1900109</elocation-id><pub-id pub-id-type="pmid">31321850</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Alonso</surname><given-names>L</given-names></name><etal/></person-group><article-title>Transcription factor activities enhance markers of drug sensitivity in cancer</article-title><source>Cancer Res</source><year>2017</year><volume>78</volume><fpage>769</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-1679</pub-id><pub-id pub-id-type="pmcid">PMC6522379</pub-id><pub-id pub-id-type="pmid">29229604</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Meer</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><fpage>D923</fpage><lpage>D929</lpage><pub-id pub-id-type="doi">10.1093/nar/gky872</pub-id><pub-id pub-id-type="pmcid">PMC6324059</pub-id><pub-id pub-id-type="pmid">30260411</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasaikar</surname><given-names>SV</given-names></name><name><surname>Straub</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><fpage>D956</fpage><lpage>D963</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx1090</pub-id><pub-id pub-id-type="pmcid">PMC5753188</pub-id><pub-id pub-id-type="pmid">29136207</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravarty</surname><given-names>D</given-names></name><etal/></person-group><article-title>OncoKB: A precision oncology knowledge base</article-title><source>JCO Precis Oncol</source><year>2017</year><volume>1</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1200/PO.17.00011</pub-id><pub-id pub-id-type="pmcid">PMC5586540</pub-id><pub-id pub-id-type="pmid">28890946</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sondka</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers</article-title><source>Nat Rev Cancer</source><year>2018</year><volume>18</volume><fpage>696</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0060-1</pub-id><pub-id pub-id-type="pmcid">PMC6450507</pub-id><pub-id pub-id-type="pmid">30293088</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cancer genome landscapes</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>1546</fpage><lpage>1558</lpage><pub-id pub-id-type="doi">10.1126/science.1235122</pub-id><pub-id pub-id-type="pmcid">PMC3749880</pub-id><pub-id pub-id-type="pmid">23539594</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upadhya</surname><given-names>SR</given-names></name><name><surname>Ryan</surname><given-names>CJ</given-names></name></person-group><article-title>Experimental reproducibility limits the correlation between mRNA and protein abundances in tumor proteomic profiles</article-title><source>Cell Rep Methods</source><year>2022</year><volume>2</volume><elocation-id>100288</elocation-id><pub-id pub-id-type="doi">10.1016/j.crmeth.2022.100288</pub-id><pub-id pub-id-type="pmcid">PMC9499981</pub-id><pub-id pub-id-type="pmid">36160043</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Vega</surname><given-names>F</given-names></name><etal/></person-group><article-title>Oncogenic signaling pathways in The Cancer Genome Atlas</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>321</fpage><lpage>337</lpage><elocation-id>e10</elocation-id><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.035</pub-id><pub-id pub-id-type="pmcid">PMC6070353</pub-id><pub-id pub-id-type="pmid">29625050</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanehisa</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>S</given-names></name></person-group><article-title>KEGG: kyoto encyclopedia of genes and genomes</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><fpage>27</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/nar/28.1.27</pub-id><pub-id pub-id-type="pmcid">PMC102409</pub-id><pub-id pub-id-type="pmid">10592173</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>L-G</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>Q-Y</given-names></name></person-group><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><year>2012</year><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmcid">PMC3339379</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>mRNA-protein correlations across issues and cancer-related pathways.</title><p><bold>a</bold> Distribution of mRNA-protein correlations across tissues in the ProCan-DepMapSanger dataset. Only tissues with at least 10 cell lines are shown. <bold>(b, c)</bold> Histogram of mRNA-protein correlations across each cohort for <bold>b</bold> ProCan-DepMapSanger, <bold>c</bold> Clinical Proteomic Tumor Analysis Consortium (CPTAC; left) and Cancer Cell Line Encyclopedia (CCLE; right) datasets, with median indicated. <bold>d</bold> Boxplot showing median mRNA-protein correlations by tissue in the ProCan-DepMapSanger dataset for key biological and selected cancer-related pathways from Sanchez-Vega et al <sup><xref ref-type="bibr" rid="R23">23</xref></sup> and KEGG<sup><xref ref-type="bibr" rid="R24">24</xref></sup>, displayed similarly to data shown in Ghoshdastider et al <sup><xref ref-type="bibr" rid="R13">13</xref></sup>. <bold>e</bold> Correlation of median mRNA-protein correlations per tissue for CPTAC with ProCan-DepMapSanger (left) and with CCLE (right), for pathways in Fig. d and <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 1c</xref>.</p></caption><graphic xlink:href="EMS206960-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>mRNA-protein correlations of cancer driver genes from OncoKB in the ProCan-DepMapSanger Dataset.</title><p><bold>a</bold> Heatmap of mRNA-protein correlations across tissue types for cancer driver genes from OncoKB<sup><xref ref-type="bibr" rid="R19">19</xref></sup>, with clusters identified by hierarchical clustering using Euclidean distance. <bold>b</bold> Violin plot showing mRNA-protein correlations of cancer driver and non-driver genes with median and standard deviation indicated. **** indicates P &lt; 0.0001 by unpaired Student’s t-test. <bold>c</bold> Distribution of mRNA-protein correlations for genes in each cluster identified in <bold>a.</bold> Gene ontology terms with q-value &lt; 0.05 are shown for each cluster. For all plots, only genes observed in at least ten samples in a minimum of fourteen tissues (i.e., missing in five or fewer tissues) are considered.</p></caption><graphic xlink:href="EMS206960-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Integration of protein reproducibility ranks and gene-specific mRNA-protein correlations.</title><p><bold>a</bold> Association between aggregated protein reproducibility ranks from Upadhya et al <sup><xref ref-type="bibr" rid="R22">22</xref></sup> and mRNA-protein correlations in the ProCan-DepMapSanger dataset. Aggregated protein reproducibility ranks are binned (upper), with the Spearman’s correlation from unbinned data shown (lower). <bold>b</bold> Scatter plot of mRNA-protein correlation against aggregated protein reproducibility rank, with cancer drivers indicated by triangle data points. Labels indicate genes highlighted in the text and shown in <bold>c. c</bold> For each gene indicated in <bold>b,</bold> plots show the distribution of mRNA-protein correlations across tissues in the ProCan-DepMapSanger (pink solid line), Clinical Proteomic Tumor Analysis Consortium (CPTAC; light dashed line) and Cancer Cell Line Encyclopedia (CCLE; dark dashed line) datasets. Background (grey solid line) indicates the median mRNA-protein correlation from all genes in the ProCan-DepMapSanger dataset. Only tissues with data from a minimum of ten samples are included. <bold>d</bold> mRNA-protein correlation of CTNNB1 for each tissue type. <bold>e</bold> Distribution of CTNNB1 mRNA expression across samples from the ProCan-DepMapSanger dataset, with outliers (&gt; 3 standard deviations above the mean) indicated. <bold>f</bold> Scatterplot showing mRNA expression and protein abundance for CTNNB1 (upper) and distribution of CTNNB1 protein abundance (lower) across samples in the ProCan-DepMapSanger dataset. Outliers indicated in<bold>f</bold> are those calculated from mRNA expression data in <bold>e.</bold></p></caption><graphic xlink:href="EMS206960-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Example output from <italic>OnCorr</italic> web tool.</title><p>A screenshot from the <italic>OnCorr</italic> web tool showing mRNA-protein correlations for EGFR, with (tissue-specific data from lung.</p></caption><graphic xlink:href="EMS206960-f004"/></fig></floats-group></article>